- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RACURA ONCOLOGY LTD: Racura Oncology Adelaide Investor Briefing | - | ASX | ||
| Di | Daily Special: OD6 Metals, Australian Rare Earths, X2M Connect, Altair Minerals, Racura Oncology | 2 | Finance News Network | ||
| Di | RACURA ONCOLOGY LTD: Notification regarding unquoted securities - RAC | - | ASX | ||
| Di | Racura Oncology Opens Korean Recruitment for RC220 Phase 1 Solid Tumours Trial | 1 | smallcaps.com.au | ||
| Di | RACURA ONCOLOGY LTD: CPACS Trial Opens for RC220 Patient Enrolment in Korea | - | ASX | ||
| 25.08. | Racura Oncology Ltd Full Year Loss Rises | 1 | RTTNews | ||
| 25.08. | RACURA ONCOLOGY LTD: Corporate Governance Statement | - | ASX | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 25.08. | RACURA ONCOLOGY LTD: Appendix 4G | - | ASX | ||
| 25.08. | RACURA ONCOLOGY LTD: Appendix 4E & Annual Report | - | ASX | ||
| 29.07. | RACURA ONCOLOGY LTD: Racure Oncology Techknow Invest Presentation | 1 | ASX | ||
| 29.07. | RACURA ONCOLOGY LTD: First HARNESS-1 Patient Safely Treated with RC220 | 2 | ASX | ||
| 28.07. | RACURA ONCOLOGY LTD: June 2026 Quarterly Activities Report and Appendix 4C | 1 | ASX | ||
| 24.07. | HotCopper Highlights, Week 30: American T&A acquisition, PolyNovo pressure, & Racura trials | 2 | The Market Online Australia | ||
| 13.07. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 09.07. | RACURA ONCOLOGY LTD: Racura to Present CPACS Data at GCOS 2026 | - | ASX | ||
| 06.07. | RACURA ONCOLOGY LTD: Racura Oncology New Zealand Investor Events | - | ASX | ||
| 03.07. | Racura Oncology (ASX:RAC) unlocks two top-tier cancer centres for HARNESS-1 enrolment push | 1 | Stocks Down Under | ||
| 03.07. | RACURA ONCOLOGY LTD: Bellberry Ethics Approval Activates New HARNESS Trial Sites | - | ASX | ||
| 02.07. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 25.06. | Racura doses first patient in lung cancer combination trial | 1 | Investing.com |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? |
RACURA ONCOLOGY LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,34 % bei einem Aktienkurs von 1,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.